Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Recruiting
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Recruiting
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Johns Hopkins University Medical Center, Baltimore, Maryland +4 locations
Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Benefits of Endoscopic Bariatric Procedures
Recruiting
This 12-months long pilot study will include patients undergoing an endoscopic procedure (endoscopic sleeve gastroplasty \[ESG\] or transoral outlet reduction \[TORe\]) as clinically indicated, and subsequent follow up clinic visits for up to one year.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/23/2024
Locations: Liliana Bancila, Los Angeles, California
Conditions: Obesity
Evaluation of Improved Onboard Patient Imaging
Recruiting
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any chang... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Treatment of Hemophilia A Patients With FVIII Inhibitors
Recruiting
This is a non-interventional, multicenter, observational, international study in male persons with haemophilia A who have developed inhibitors to any replacement coagulation factor VIII (FVIII) product. The purpose of the study is to capture different approaches in the management of persons with haemophilia A and FVIII inhibitors, document current immune tolerance induction approaches, and evaluate the efficacy and safety of immune tolerance induction, including the combination of FVIII and emic... Read More
Gender:
MALE
Ages:
All
Trial Updated:
08/23/2024
Locations: Arthur M. Blank Hospital, Atlanta, Georgia +1 locations
Conditions: Hemophilia A
@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms
Recruiting
The primary aim of the SwissNeuroFoundation AneurysmDataBase Project is to implement information technology based tools to create and use a holistic reference database specific to intracranial aneurysms (IA). The SwissNeuroFoundation AneurysmDataBase are concerned with generating the data with which to populate this database. The purpose for populating the database are to: * Screen for and evaluate markers of risk for intracranial aneurysm formation and aneurysm rupture. Are considered as mar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: University of California, San Francisco, California +18 locations
Conditions: Intracranial Aneurysm
Message Framing and Policy Support for Front-of-package Labeling
Recruiting
This study aims to assess whether different message framing about front-of-package labeling policies elicits more policy support than the control (no framing) among Latino and limited English proficiency populations. The study also seeks to identify which message framing elicits the most policy support.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/23/2024
Locations: The University of North Carolina at Chapel Hill's Gillings School of Global Public Health, Chapel Hill, North Carolina
Conditions: Diet, Healthy
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Recruiting
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Gender:
ALL
Ages:
Between 15 years and 70 years
Trial Updated:
08/23/2024
Locations: University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California +17 locations
Conditions: B-cell Acute Lymphoblastic Leukemia
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, Alabama +59 locations
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
Recruiting
This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvali... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/23/2024
Locations: University of Colorado, Aurora, Colorado +5 locations
Conditions: Phenylketonuria (PKU)
Phase I Study in Advanced Malignancies With 5-ALA
Recruiting
RDT aims to take advantage of the relatively safer toxicity profiles of both lower dose radiation therapy and systemic ALA to treat non-superficial lesions in a manner similar to photodynamic therapy. The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, with administration of ALA, which has been shown to be selectively concentrated in neoplastic cells, it is reasonable to expect responses in the target lesion(s) with relative sparing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Solid Tumor
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Recruiting
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
08/23/2024
Locations: The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas +6 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer